Fool - Investing News·1d ago
3 High-Yield Healthcare Stocks to Buy With $1,000 and Hold Through Any MarketThey are so much more than just dividend stocks.
Pfizer's top line has stalled, with 2026Q3 revenue of $16.6B reflecting year-over-year growth of -0.4%, suggesting the post-pandemic revenue base is plateauing rather than re-accelerating.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue has plateaued near $14B-$17B per quarter with 2026Q3 growth of -0.4%, while gross margin swung between 67.3% and 75.7% and operating margin compressed to 21.0% in 2025Q4 from 33.7% in 2025Q1, suggesting operating income is not scaling with gross profit.
Pfizer's oncology drugs like Padcev, Lorbrena, and Talzenna are performing well, with pivotal trials for weight-loss drugs planned for 2026.
The company's strategy includes acquiring and developing new products, which could enhance revenue.
Technical analyses suggest a potential stabilization above $25.00, with targets of $28.00-$29.00.
Key products like Eliquis and Ibrance will lose patent protection between 2026 and 2030, potentially impacting revenues by $1.5 billion in 2026.
Sales from the COVID-19 vaccine and antiviral are expected to decline further in 2026, affecting overall revenue.
Competition in breast cancer treatments and obesity drugs from companies like Eli Lilly and Novo Nordisk could erode market share.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 3, 2026 | $0.87+18.4% vs $0.73 | $16.6B+4.6% vs $15.9B |
Q3 2026 Aug 4, 2026 | $0.77+12.9% vs $0.68 | $15.0B+4.4% vs $14.4B |
Q2 2026 May 5, 2026 | $0.75+3.9% vs $0.72 | $14.5B+4.4% vs $13.8B |
Q1 2026 Feb 3, 2026 | $0.66+16.4% vs $0.57 | $17.6B+4.2% vs $16.8B |
They are so much more than just dividend stocks.
A quarter that produced a surprise profit and a bigger 2026 forecast is sending Moderna (NASDAQ:MRNA | MRNA Price Prediction) higher again. Moderna stock is at $254.07 in morning trading, up 5%.
Six S&P 500 'safer' high-yield dividend stocks—Regions Financial, Ford, AT&T, Pfizer, Verizon, VICI Properties—currently offer attractive buy signals based on free cash flow yields. Analyst projections for the top ten S&P 500 dividend dogs indicate potential net gains of 14.54% to 40.07% by November 2027, with an average estimated gain of 27.42%. Dividend dog strategy favors stocks where annual dividends from $1,000 invested exceed single-share prices and free cash flow yields surpass dividend yields.
The Fund returned 3.18% compared to a 2.61% return for the Russell 1000 Value Index. Key contributors include Microsoft, Salesforce and Thermo Fisher Scientific. Key detractors include Aon, Carrier Global and Builders FirstSource.
Benchmark PFE against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Pfizer Inc. (PFE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $29.39 | $167.51B | 21.61 | -1.65% | 12.42% | 8.87% | 5.85% | |
| $276.22 | $664.92B | 25.04 | 6.05% | 16.5% | 19.86% | 1.85% | |
| $146.71 | $362.35B | 20.15 | 1.18% | 4.78% | 6.59% | 2.22% | |
| $291.31 | $514.68B | 122.92 | 8.57% | 15.68% | 286.66% | 2.26% | |
| $1354.00 | $1.28T | 59.00 | 44.7% | 31.9% | 83.64% | 0.44% | |
| $62.14 | $126.89B | 18.01 | -0.22% | 18.47% | 43.84% | 3.98% |
Pfizer Inc. (PFE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Pfizer Inc. (PFE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 3, 2026·SEC
Nov 3, 2026·SEC
Aug 4, 2026·SEC
Get notified when PFE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Pfizer Inc. (PFE) stock FAQ — growth, dividends, profitability & financials explained
Pfizer Inc. (PFE) reported $63.63B in revenue over the trailing twelve months. Revenue was $62.58B in fiscal year 2025. That is 454% more than the $11.31B of fiscal year 1996.
Pfizer Inc. (PFE) revenue fell by 1.6% in fiscal year 2025, compared with the prior fiscal year.
Yes. Pfizer Inc. (PFE) earned $4.04B in net income over the trailing twelve months (a 6.3% net margin).
Yes. Pfizer Inc. (PFE) pays a dividend that yields 5.85% at the current price, a high yield.
Pfizer Inc. (PFE) had a return on equity (ROE) of 8.9% in fiscal year 2025. That is below the market's typical 10-15%.
Pfizer Inc. (PFE) generated $11.79B in free cash flow over the trailing twelve months.
